RUNX3 is a tumor suppressor that is silenced in cancer following hypermethylation of its promoter. The effects of hypoxia in tumor suppressor gene (TSG) transcription are largely unknown. Here, we investigated hypoxia-induced silencing mechanisms of RUNX3. The expression of RUNX3 was downregulated in response to hypoxia in human gastric cancer cells at the transcriptional level. This downregulation was abolished following treatment with the histone deacetylase (HDAC) inhibitor trichostatin A (TSA) and cytosine methylation inhibitor 5-aza-2-deoxycytidine (5-Aza), suggesting that an epigenetic regulatory mechanism may be involved in RUNX3 silencing by hypoxia. DNA methylation PCR and bisulfite-sequencing data revealed that hypoxia did not affect the methylation of RUNX3 promoter. A chromatin immunoprecipitation (ChIP) assay revealed increased histone H3-lysine 9 dimethylation and decreased H3 acetylation in the RUNX3 promoter following hypoxia. Hypoxia resulted in the upregulation of G9a histone methyltransferase (HMT) and HDAC1; additionally, overexpression of G9a and HDAC1 attenuated RUNX3 expression. The overexpression of G9a and HDAC1, but not their mutants, inhibited the nuclear localization and expression of RUNX3. Diminished mRNA expression and nuclear localization of RUNX3 during hypoxia was abolished by siRNA-mediated knockdown of G9a and HDAC1. This study suggests that hypoxia silences RUNX3 by epigenetic histone regulation during the progression of gastric cancer.
Introduction
Epigenetic changes in conjunction with genetic alterations result in aberrant or total loss of expression of somatic gene products in cancer development (Baylin and Herman, 2000; Momparler, 2002) . The methylation of CpG islands in the promoter regions of genes leads to the silenced expression and is a normal event in the regulation of cellular gene expression. Aberrant patterns of DNA methylation associated with tumor suppressor genes (TSGs) occur early in tumor development and increase progressively, eventually leading to a malignant phenotype (Johnstone, 2002) . DNA methyltransferase (DNMT) genes play a critical role in de novo and sustained CpG island methylation in the gene promoter; these genes recruit histone deacetylases (HDACs) to chromatin (Yoder et al., 1997; Liu et al., 1998; Okano et al., 1999; Robertson et al., 1999 Robertson et al., , 2000 . The association of methyl-CpG-binding domain protein family members, such as methyl-CpG-binding protein 2, to a methylated promoter represses transcription. Methyl-CpG-binding protein 2 is associated in vivo with HDACs (Nan et al., 1997) and another chromosome modifier, Mi-2, a member of the SWI2/SNF2 family of ATPases (Jones et al., 1998; Nan et al., 1998; Wade et al., 1999) . These reports suggest possible cross talk between cytosine methylation and histone modification. It has also been demonstrated that the elimination of H3-K9 methylation in Neurospora results in the loss of DNA methylation (Tamaru and Selker, 2003) . These data suggest a functional linkage and sequential interplay between DNA and H3-K9 methylation in the formation of the heterochromatic state. Further, treatment of tumor cells with a DNA methyltransferase inhibitor (5-Aza) reduced the level of H3-K9 methylation in the promoter region of TSG independently of cytosine methylation (Nguyen et al., 2002) , suggesting a novel function of 5-Aza in histone modification.
Post-translational modification of histones can control gene activity. Specifically, modification of the N-terminal group of histone lysine residues by acetylation or deacetylation remodels the structure of nucleosomes. HDACs remove the acetyl group from lysine, thereby reversing the open chromatin structure and silencing gene expression. The aberrant deacetylation of histones in nucleosomes is probably because of altered specificity or activity of HDACs and may be involved in neoplastic progression (Johnstone, 2002) . The methylation of lysine residues in histones by specific histone methyltransferases (HMTs) has also been implicated alterations of chromatin structure and gene regulation. The methylation of K9 or K27 as well as demethylation of K4 in histone H3 have been associated with condensed chromatin and the silencing of genes (Fahrner et al., 2002) .
RUNX3 is a runt-domain transcription factor and is known to be a tumor suppressor in gastric cancer, as RUNX3À/À mouse gastric mucosa exhibit hyperplasia on account of stimulation of proliferation and suppression of apoptosis. RUNX3 is frequently inactivated in gastric cancers by hemizygous deletion and hypermethylation of its promoter region (Li et al., 2002) . Loss of RUNX3 affects the clinical outcome of gastric cancer patients and has been suggested to be related to tumor growth and metastasis (Wei et al., 2005) . Levels of RUNX3 protein are post-translationally regulated through acetylation and ubiquitination through transforming growth factor-b signaling (Jin et al., 2004) , suggesting that RUNX3 silencing could be induced by growth factors secreted from the tissue microenvironment. In contrast, transcriptional repression of RUNX3 is highly associated with CpG hypermethylation of the RUNX3 promoter in gastric (Li et al., 2002; Wei et al., 2005) and lung cancers . To date, DNA promoter methylation of RUNX3 is the only mechanism shown to suppress transcription of the RUNX3 gene. However, other mechanisms by which RUNX3 expression is regulated at the transcriptional level remain largely unknown.
Hypoxia is commonly found in solid tumors larger than 1 mm 3 and is a strong stimulator of tumor angiogenesis (Bunn and Poyton, 1996; Semenza, 2003) . Hypoxia stabilizes hypoxia inducible factor (HIF)-1a and increases HIF-1a-mediated downstream gene transcription involved in cell survival, angiogenesis, apoptosis and glycolysis (Harris, 2002) . Recent evidence suggests the involvement of hypoxia in early tumorigenesis through the suppression of TSGs (for example, p53, pVHL and MLH1) in cancer cells (Kim et al., 2001; Mihaylova et al., 2003) as well as double-strand break repair genes both in cancer and normal cells (Meng et al., 2005) . P53 and pVHL are downregulated following the increased HDAC activity in hypoxia (Kim et al., 2001) . MLH1 expression is restored by 5-Aza or trichostatin A (TSA) treatment, suggesting that epigenetic mechanisms may be involved in hypoxic gene silencing (Mihaylova et al., 2003) . A more recent study found that the downregulation of MLH1 during hypoxia is because of histone H3 dimethylation through HMT and G9a (Chen et al., 2006) . Because hypoxic conditions may arise during hyperplasia in the early stages of neoplastic transformation and tumor progression, we investigated whether a hypoxic microenvironment could regulate RUNX3 expression. We found that RUNX3 silencing by hypoxia is mediated by epigenetic histone modification and may play a role during the progression of gastric cancer.
Results
Hypoxia downregulates RUNX3 mRNA transcription in gastric cancer cells RUNX3 is silenced in many gastric cancer cells. SNU1, 216, 601, 638 and 668 cells did not express RUNX3 genes at baseline conditions. SNU5, 16, 484, 719, MKN1 and MKN45 cells expressed RUNX3 mRNA, and hypoxia significantly decreased the level of RUNX3 expression in all these cells except for SNU5 and SNU484 (Figure 1a) . The expression pattern of RUNX3 protein in these cells was slightly different from that of mRNA. In SNU16 and SNU719 cells, RUNX3 protein was barely detected, but in SNU5 and SNU484 cells, hypoxia clearly inhibited the expression of protein but not the mRNA expression level. Because the RUNX3 protein level is regulated by the activity of other proteins (Huang et al., 2007) , the protein and mRNA levels of RUNX3 may not always coincide. To confirm this result, we selected three cell lines expressing RUNX3 supposedly under transcriptional regulation during hypoxia. These cells were exposed to various hypoxic intervals, and their gene expression was assayed using real-time reverse transcriptase PCR (RT-PCR). RUNX3 expression decreased significantly after 16 h and was almost completely eliminated after 36 h in SNU16, MKN1 and MKN45 cells as determined by both realtime ( Figure 1b ) and semiquantitative RT-PCR (data not shown). Because the expression level in SNU16 was less than in the other cells, RUNX3 was completely silenced after 36 h of hypoxia in all these cells.
We next determined whether the reduced expression of RUNX3 mRNA under hypoxia was the result of increased mRNA degradation. The remaining amounts of RUNX3 mRNA under normoxia or hypoxia were determined at various time points after the addition of the transcriptional inhibitor actinomycin D to MKN45 cells. There were no significant differences at any time (Figure 1c ), suggesting that decreased RUNX3 mRNA expression under hypoxia largely occurs through the suppression of transcription.
The epigenetic regulatory agents 5-Aza and TSA were utilized to examine the role of epigenetic mechanisms in the silencing of RUNX3 by hypoxia. Both 5-Aza and TSA abolished hypoxic RUNX3 silencing (Figure 1d ). The combination of 5-Aza and TSA had a similar restorative effect on RUNX3 repression, but had no effect under normoxia. This result suggests that either DNA/histone methylation or histone deacetylation is involved in RUNX3 silencing by hypoxia, as 5-Aza reduces H3-K9 dimethylation through a mechanism independent of its effect on cytosine methylation (Nguyen et al., 2002) .
DNA promoter methylation is not involved in hypoxic RUNX3 silencing in gastric cancer cells To determine whether hypoxia could regulate RUNX3 promoter methylation, we performed methylation-specific PCR with primers designed to amplify the RUNX3 promoter region in RUNX3-expressing gastric cancer cells. All cells showed unmethylated PCR product, whereas methylated PCR product was found only in SNU16. The unmethylated and methylated band patterns did not change under hypoxic conditions (Figure 2a ). To confirm this finding, we performed bisulfite genomic sequencing on PCR products. Methylcytosines in CpG sites (underlined) remained as cytosines after sodium bisulfate modification, whereas other cytosines (non-CpG sites) were converted to uracil. In SNU16 cells, methylated and unmethylated CpG sites were both present under normoxia, as well as with 24 or 72 h hypoxia (Figure 2b , first column, mixed peaks in third CG sequence for C and T, bar region); this result was consistent with the data showing mixed methylated and unmethylated methylation-specific PCR bands (Figure 2a) . In MKN1 and MKN45 cells, there was no evidence of hypoxic methylation of CpG sites ( Figure 2b , center and right columns). These results indicate that even with long-term hypoxia (72 h), RUNX3 DNA promoter methylation is not induced.
When we checked the level of DNMTs, DNMT1 and DNMT3a, the level of DNMT1 was not changed by hypoxia and only decreased in SNU16 cells. DNMT3a, involved in de novo methylation, was also mostly unaffected; it slightly decreased in SNU16 and MKN45 cells under hypoxia (Figure 2c ). These results suggest that hypoxia does not affect DNA methylation in the RUNX3 promoter region, nor does it affect the expression of DNMTs.
Histone methylation is involved in hypoxic RUNX3 silencing in gastric cancer cells Because it has been reported that 5-Aza attenuates H3-K9 methylation of TSG through a mechanism that is independent of DNA CpG island methylation (Nguyen et al., 2002) , the histone methylation status during hypoxia was further determined. In SNU16, MKN1 and MKN45 cells, histone H3-K9 dimethylation (H3K9me2) was increased after 24 or 48 h of hypoxia ( Figure 3a) . However, the kinetics of H3K9me2 increase varied among these three cell lines. Hypoxia increased the level of H3K9me2 at 24 h but decreased it 48 h in MKN1 and MKN45 cells, whereas the level of of H3K9me2 was increased at 48 h in SNU16 cells. As H3-K4 trimethylation (H3K4me3) is known to be involved in gene activation (Nguyen et al., 2002) , we also examined H3K4me3 levels. As expected, H3K4me3 RUNX3 levels in cell extracts prepared at various time points after hypoxia exposure were checked by real-time RT-PCR. Relative expression of RUNX3 was normalized against GAPDH was calculated and graphed. Significant differences from control were noted as *Po0.05 and # Po0.01. (c) RUNX3 mRNA expression was determined under normoxia or hypoxia by real-time RT-PCR. MKN1 cells were incubated under normoxia or hypoxia for 6, 12, 24 or 48 h in the presence of actinomycin D (5 mg/ml). RUNX3 mRNA transcript levels detected in normoxic control cells at 0 h were set to 100% and those in each sample were normalized against GAPDH and calculated as relative amounts of the control. (d) RUNX3 expression was determined after treatment with a methylation and/or a deacetylation inhibitor. MKN45 cells were cultured for 24 h in the presence of 5-Aza (100 mM) and/or TSA (300 nM) or no drug as a control under hypoxic conditions. N, normoxia; H, hypoxia; A, 5-Aza; T, TSA; GAPDH; glyceraldehyde 3-phosphate dehydrogenase; RT-PCR, reverse transcriptase PCR; TSA, trichostatin A.
was completely diminished following hypoxia in SNU16 cells ( Figure 3a) .
To determine whether increased H3-K9 methylation during hypoxia was involved in RUNX3 silencing, a chromatin immunoprecipitation (ChIP) assay was performed using an antihuman H3-K9 dimethylated antibody. Under hypoxic conditions, H3K9me2 in the RUNX3 promoter was significantly increased by 2-2. 6-fold in MKN45 cells when compared to the normoxic condition ( Figure 3b ). These results indicate that hypoxia stimulates histone methylation involved in gene silencing in the RUNX3 promoter region.
Recently, it has been reported that G9a HMT modulates H3K9me2 in hypoxia (Chen et al., 2006) . Thus, we investigated whether the H3K9me2 in the RUNX3 promoter is mediated by G9a HMT. The G9a HMT level was initially shown to increase in gastric cancer cells under hypoxia, as shown in Figure 3c . This pattern of increased G9a protein expression was consistent with that of H3K9me2 ( Figure 3a ). Suv39h1, another HMT involved in H3K9 methylation in pericentric heterochromatin was also upregulated by hypoxia ( Figure 3c ). Moreover, the overexpression of G9a in MKN1 cells brought RUNX3 levels in normoxia to a level similar to that observed in mock transfectants under hypoxia; hypoxic cells showed further silencing when transfected with wild-type G9a. However, RUNX3 inhibition was not induced in SET deletion mutant (DSET) transfectants under normoxia or hypoxia ( Figure 3d ). These results indicate that increased G9a HMT suppressed RUNX3 gene under hypoxia.
Histone deacetylation is involved in RUNX3 downregulation following hypoxia Next, we investigated the involvement of HDAC and histone deacetylation in the suppression of RUNX3 by hypoxia. Hypoxia increased the HDAC1 protein level and decreased histone H3 acetylation concomitantly with RUNX3 downregulation (Figure 4a ). To determine whether HDAC activation is involved in RUNX3 downregulation by hypoxia, we transfected cells with wild-type HDAC1 (HDAC1) or a mutant (mtHDAC1) expression vector. In HDAC1-transfected MKN1 cells, RUNX3 was downregulated to a level similar to that observed in hypoxic mock transfectants, but not Figure 2 Methylation status of RUNX3 promoter regions and DNMT level in hypoxia in gastric cancer cell lines. Cells were exposed to hypoxia for 24 h or 72 h. (a) Methylation-specific PCR analysis of RUNX3 was performed with genomic DNA isolated from indicated five gastric cancer cell lines as described in Materials and methods. Methylation was detected by the presence of a PCR product amplified by methylation-specific primers in the M lanes, demethylation was detected using PCR products amplified with unmethylated-specific primers in the U lanes. DW denotes bisulfite-treated distilled water which served as a negative control. H24 is hypoxic exposure for 24 h and H72 is for 72 h. (b) Bisulfite sequencing of RUNX3 promoter CpG islands in SNU16, MKN1 and MKN45 cell lines after exposure to hypoxia for 24 h or 72 h. Unmethylated cytosines (C) are converted to uracil (T). The presence of a C preceding a G in the site indicated by a black bar show that these cytosines were methylated, whereas the presence of T instead of C in the same positions shows that these Cs were unmethylated. (c) Expression of DNMTs in the indicated five gastric cancer cell lines. Western blot analysis was performed for DNMT1 and DNMT3a detection in cells exposed to normoxia or hypoxia for 24 h. DNMT, DNA methyltransferase. mtHDAC1 transfectants, under normoxic conditions (Figure 4b ). In hypoxic conditions, transfection of HDAC1, but not mtHDAC1, resulted in greater downregulation of RUNX3 than the control. These results suggest that HDAC1 activity might be involved in hypoxic RUNX3 downregulation.
The apparent involvement of both G9a and HDAC1 in hypoxic RUNX3 silencing may permit cell-specific differences in histone methylation and deacetylation kinetics during hypoxia. We, thus, checked HDAC1 and acetylated H3 levels depending on hypoxia exposure time. HDAC1 was significantly upregulated at 24 and 48 h of hypoxia in SNU16 and MKN1 cells, but only at 48 h in MKN45 cells (Figure 4c ). This pattern was slightly different from that of G9a or H3K9me2 (Figures 3a and c) . However, the combined expression pattern of HDAC1 and G9a/H3K9me2 clearly show silencing of RUNX3 in these three cell lines from 16-24 to 48 h after initiation of hypoxia (Figure 1b) . H3-acetylation and HDAC1 expression were inversely correlated at different times of hypoxic exposure in all cells (Figure 4c ).
To verify that histone acetylation was decreased in the RUNX3 genes, a ChIP assay was performed. As shown in Figure 4d , hypoxia decreased the binding of acetylated H3 to the RUNX3 promoter in vivo. Compared to the input control, promoter acetylation of H3 during normoxia was about 2.5-3-fold higher than in hypoxia. These results indicate that hypoxia increased HDAC activity and its recruitment to the promoter for deacetylation of histone H3, thereby generating a heterochromatin structure that suppressed RUNX3 gene transcription.
We identified that methylation of histone H3-K9 was increased by hypoxia, and that 5-Aza treatment dramatically decreased this methylation (Figure 4e ). This is consistent with a previous report (Nguyen et al., 2002) . However, 5-Aza treatment did not change the acetylation level, whereas TSA affected the methylation status and attenuated the hypoxic suppression of G9a and HDAC1 as well as hypoxia decrease the nuclear localization of RUNX3 Next, we tested the roles of hypoxia, G9a and HDAC1 in the silencing and cellular expression pattern of RUNX3. RUNX3 was expressed in both the cytosol and nucleus in normoxia, but the expression was limited to the cytosol in hypoxic fractions or in cells overexpressing HDAC1 and/or G9a (Figure 5a ). Overexpression of G9a HMT and HDAC1 resulted in noticeably decreased nuclear localization of RUNX3 (Figure 5b ). However, G9a-DSET and HDAC1 mutants did not show altered localization of RUNX3. Similarly, hypoxia also decreased the nuclear localization of RUNX3 (Figures 5a and b) .
To determine whether G9a and HDAC1 are crucial for hypoxia-induced RUNX3 downregulation, we adopted a small interfering (si) RNA strategy. We made two different siRNAs covering two different sites of each gene (G9a and HDAC1) and checked their ability to inhibit expression. As shown in Figure 6a , treatment with G9a and HDAC1 siRNAs successfully decreased the mRNA level of the respective target genes. G9a siRNA no. 2 and HDAC1 siRNA no. 1 showed the most effective repression. When we transfected MKN1 cells with scrambled siRNA as a control, hypoxia inhibited the expression of RUNX3. However, knockdown of G9a or HDAC1 by siRNA did not inhibit RUNX3 expression. Silencing of G9a or HDAC1 by siRNA no. 2 or SNU16, MKN1 and MKN45 cells were exposed to normoxia or hypoxia for the indicated times and analysed using western blots with anti-HDAC1 and anti-H3-Ace antibodies. Quantitation of each band for HDAC1 (upper) and acetylated H3 (bottom) relative to atubulin is shown in the graph at right. Significant differences were noted as Po0.01 compared to normoxic control level. (d) ChIP assays were performed as described in Figure 3 . MKN45 cells were treated with normoxia or hypoxia for 24 h, and RUNX3 promoter DNA was immunoprecipitated with an antibody specific for H3-Ace, and then analysed with primers amplifying RUNX3 promoter regions (À1618 and À1307); Ip, input DNA. Ac, DNA combined with acetylated histone H3. Relative differences (ratio) in the levels of immunoprecipitated DNA (from cell lysate under different conditions) were quantified and shown at the bottom by the UV intensity of the DNA bands. Results from three separate experiments are presented as the ratio of immunoprecipitant (IP) to input (Ip). *, between normoxia (N) and hypoxia (H), Po0.01. (e) Effect of 5-Aza and TSA as single agents or in combination on H3K9me2 and H3-Ace in MKN45 cells under hypoxia for 24 h. Western blotting was performed after treatment with 100 mM 5-Aza (A) and/or 300 nM TSA (T) under hypoxia exposure for 24 h. The numbers below the bands in each lane indicate the fold induction calculated by relative band density normalized against the internal control using the ImageJ program. ChIP, chromatin immunoprecipitation; c, control, DAPI, 4',6-diamidino-2-phenylindole; HDAC, histone deacetylase; FITC, fluorescein isothiocyanate; RT-PCR, reverse transcriptase PCR; TSA, trichostatin A; UV, ultraviolet.
no. 1 prominently reversed the suppression of RUNX3 by hypoxia (Figure 6b ). Application of these siRNAs resulted in the localization of RUNX3 into the nucleus even under hypoxic condition (Figures 6c and d) . Taken together, our findings suggest that hypoxia suppresses mRNA expression of RUNX3 through histone methylation and deacetylation through G9a HMT and HDAC1.
Discussion
RUNX3 is frequently inactivated in gastric cancer tissues (Li et al., 2002; Ito et al., 2005) and is highly related to metastatic outcome (Fahrner et al., 2002) . The mechanism for RUNX3 inactivation in cancer cells and tissues has been postulated to involve DNA hypermethylation in the promoter region (Li et al., 2002 ). To our knowledge, no reports have investigated hypoxic regulation of RUNX3 expression through histone modification mechanisms during cancer development. Here, we determined that RUNX3 was downregulated by hypoxia in several gastric cancer cells and this suppression was on account of histone deacetylation and methylation.
Histone deacetylase levels have been shown to be elevated in various cancer tissues and have been reported to increase following hypoxia, leading to subsequent inhibition of TSGs and stimulation of angiogenesis in hepatoma cells (Kim et al., 2001) . HDACs interact with methyl-CpG-binding protein 2 to repress transcription and promoter activities of specific TSGs, such as p53, pVHL (Nan et al., 1998) and p16 (Harris, 2002) . Our data show decreased H3 acetylation in the RUNX3 promoter region (Figure 4d ) and recovery of acetylation following treatment with Figure 5 Inhibition of nuclear expression and localization of RUNX3 by overexpression of G9a and/or HDAC1 as well as by hypoxia. (a) MKN1 cells were transfected with 3-myc-RUNX3, full-length G9a (pEGFP-hG9a) or HDAC1 and after 24 h incubated under normoxia (N) or hypoxia (H) for 24 h. Western blotting analysis with cytosolic and nuclear fractions was performed. (b) MKN1 cells were transfected with 3-myc-RUNX3, pEGFP-hG9a or SET domain deletion mutant (pEGFP-hG9aDSET) or HEK293 cells were transfected with HDAC1 full-length or mutant HDAC1 plasmids. Cells were stained with antibodies against each protein followed by a FITC-or rhodamine-labeled secondary antibody. DAPI was used for nuclear staining; magnification ¼ Â 400. C, control vector; DAPI, 4',6-diamidino-2-phenylindole; HDAC, histone deacetylase; FITC, fluorescein isothiocyanate.
TSA (Figure 4e ). Hypoxia induced HDAC1 upregulation (Figure 4c ), and expression of wild type, but not mutant, HDAC1 led RUNX3 suppression (Figure 4b ). HDAC1-targeted siRNA did not suppress RUNX3 under hypoxic conditions. These results clearly indicate that hypoxia inhibits RUNX3 promoter acetylation through increased HDAC activity.
The localization of RUNX3 in normoxic cells suggests that RUNX3 might shuffle between the cytosol and nucleus. HDAC1 expression and hypoxia resulted in clear decreases in the global cellular levels of RUNX3 as well as in nuclear localization, suggesting that functional suppression of RUNX3 during hypoxia occurs through histone deacetylation. Jin et al. (2004) demonstrated that RUNX3 expression was inhibited by HDACs through direct deacetylation of the Runt domain and C-terminal region of RUNX3 protein. Thus, the restoration of RUNX3 expression by TSA might be attributable to H3-K9 acetylation in the promoter and increased RUNX3 protein stability at the post-translational level. In this study, RUNX3 protein expression was decreased by hypoxia in SNU5 and SNU484 cells, whereas mRNA expression was not affected. Although various mechanisms regulate the stability of proteins in the RUNX family, acetylation/ deacetylation mediated by p300 or HDACs is well documented to increase or decrease the activity or stability of RUNX3 (Bae and Lee, 2006) . The hypoxic activation of HDAC (Kim et al., 2001) , which destabilizes RUNX3 in part explain the attenuation of RUNX3 protein under hypoxia in the SNU5 and SNU484 cells as well as the nuclear expression in MKN1 cells (Figure 6) . However, further experiments should be performed to specifically identify the cause of RUNX3 protein destabilization under hypoxia.
We found that hypoxic silencing of RUNX3 was not because of DNA promoter methylation even though 5-Aza, which demethylates cytosine residued in CpG islands, abolished hypoxic suppression of RUNX3. Because 5-Aza can induce hyperacetylation of pericentric heterochromatin (Takebayashi et al., 2001 ) and cause H3-K9 demethylation and H3-K4 methylation independently of its effects on DNA methylation (Nguyen et al., 2002) , H3-K9 methylation and H3-K4 demethylation are more likely candidates for involvement in RUNX3 downregulation. In this study, hypoxia was unable to induce cytosine methylation in the RUNX3 promoter even after long-term exposure (Figure 2 ), but did induce H3 deacetylation, H3-K9 methylation and H3-K4 demethylation. Additionally, treatment with 5-Aza allowed recovery of RUNX3 expression not affecting DNA methylation. To under- stand these findings, it is necessary to note that RUNX3-expressing cells (SNU16, MKN1 and MKN45), but not RUNX3-silencing gastric cancer cells, were used to check controlled silencing by hypoxia. In RUNX3-silencing gastric cancer cells, there is an abundance of promoter methylation (Li et al., 2002) , but the selected cells have little cytosine methylation at baseline conditions (Li et al., 2002) . Additionally, hypoxia might not be a severe enough stressor to induce cytosine methylation, but may still have the ability to modulate the enzymatic activity involved in heterochromatin modification in epigenetic microenvironments. It has been reported that histone deacetylation or methylation is likely to occur before DNA methylation, although they likely interact to suppress the expression of certain genes (Bachman et al., 2003; Jones and Baylin, 2007) . It is, therefore, possible that 5-Aza may not affect promoter cytosine methylation during hypoxia in RUNX3-expressing cells.
Heterochromatin formation following H3-K9 methylation and H3-K4 demethylation in cancer cells induces gene silencing of TSGs (Nguyen et al., 2002) . Some tumor suppressors are silenced by hypoxia through epigenetic changes. For example, hypoxia increases G9a HMT expressed in association with the suppression of MLH1, a TSG plays a role in DNA repair, suggesting that hypoxia leads to histone methylation and induces additional gene mutations or genomic instability. The proteins p53, pVHL (Kim et al., 2001) , BNIP3 (Shaw et al., 2006) and STAT1 (Ivanov et al., 2007) are involved in histone deacetylation, which is required to suppress transcription under hypoxia. Thus, histone modifications, such as K9 methylation, K4 demethylation and deacetylation, might primarily be induced by hypoxia to inhibit RUNX3 gene expression and may facilitate permanent gene silencing by cytosine methylation. A growing number of genetic and epigenetic alterations in tumor suppressors and tumorrelated genes have been identified to be involved in gastric carcinogenesis. In particular, the inactivation of p16, CDH1 (E-cadherin), MLH1 and RUNX3 because of promoter methylation is more frequently observed than inactivation because of mutations (Ushijima and Sasako, 2004; Anderson et al., 2006) . Interestingly, these genes are reported to be downregulated by hypoxia (Mihaylova et al., 2003; Box and Demetrick, 2004; Esteban et al., 2006; Krishnamachary et al., 2006 and our results) , although there is no evidence that hypoxia increases the DNA promoter methylation of genes. Thus, our results support the concept of interplay between histone and DNA chemical modifications (Jones and Baylin, 2007) , but the simultaneous or sequential mechanism of which has not yet been identified.
We found cell type-specific kinetic differences in induction of G9a and HDAC1 and in histone modification during hypoxia. Although many reports have examined epigenomics in cancer development, few have revealed the exact hierarchy and kinetics of histone methylation/demethylation and acetylation/deacetylation in the development of different types of cancer. However, increasing evidence suggests that histone modifications may be much more dynamically involved in the regulation of chromatin than previously believed (Gibbons, 2005) . Thus, there may be other cofactors that cooperate with such histone modifiers to silence RUNX3 with different kinetics under hypoxic conditions. Suv39h1 expression was also increased by hypoxia and may be involved in hypoxia-induced RUNX3 silencing in gastric cancer. Suv39h1 is known to target pRb promoter for promoting cell cycling (Nielsen et al., 2001) and is recruited to the RUNX3 protein as a cofactor for RUNX3-dependent gene suppression (Durst and Hiebert, 2004) . However, the role of Suv39h1 in hypoxic RUNX3 downregulation or RUNX3-mediated gene silencing remains to be determined.
Recent awareness of Helicobacter pylori infection as a gastric carcinogen is increasing; H. pylori infection is known to increase the risk of developing gastric cancer by 2.2-21-fold (Ekstrom et al., 2001; Uemura et al., 2001) , and also to increases the degree of gene methylation (Chan et al., 2003) . Thus, we are tempted to speculate that H. pylori has a causative or collaborative role in hypoxic silencing of genes, such as RUNX3, in gastric carcinogenesis. Therapeutic approaches including anti-inflammatory regimens that could diminish the hypoxic insult in gastric epithelial cells should, therefore, be considered and adopted to prevent gastric carcinogenesis and progression.
Materials and methods

Cell culture
Human gastric cancer cells, SNU1, 5, 16, 216, 484, 601, 638, 668, 719, MKN1, MKN28 and MKN45 (American Type Culture Collection and Korean Cell Line Bank, Korea) were maintained in RPMI-1640 with 10% fetal bovine serum (Hyclone) under either hypoxic (1% O 2 ) or normoxic (21% O 2 ) conditions at 37 1C. For the hypoxic conditions, hypoxic chambers (Thermo Scientific, MA, USA, and Astec, Fukuoka, Japan) were used for maintaining low oxygen tension (1% O 2 , 5% CO 2 , and balanced with N 2 ).
Semiquantitative RT-PCR and real-time RT-PCR analyses First strand cDNA was synthesized from total RNA using MMLV reverse transcriptase (Bioneer, Daejeon, Korea). The conditions for semiquantitative PCR were 35 cycles of denaturation (94 1C/30 s), annealing (50 1C/40 s), extension (72 1C/40 s) and final extension (72 1C/10 min). The primers used for RUNX3 were forward, 5 0 -GAGTTTCACCCTGACC ATCACTGTG-3 0 , reverse, 5 0 -GCCCATCACTGGTCTTGAA GGTTGT-3 0 ; and for b-actin, forward, 5 0 -GACTACCTCAT GAAGATC-3 0 , reverse, 5 0 -GATCCACATCTGCTGGAA-3 0 . Real-time RT-PCR was performed in a 7500 Real-time PCR system (Applied Biosystems, CA, USA) with SYBR premix Ex Taq (Takara, Shiga, Japan). Real-time RT-PCR was carried out with specific primers for RUNX3 and glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The PCR program consisted of an initial denaturation step at 95 1C for 10 s, followed by 40 cycles of 95 1C for 5 s and 60 1C for 1 min. The expression level of each specific gene was normalized against the expression of GAPDH in the same master reaction. The primers for RUNX3 were CATCAAGGTGACCGTGGAC and GTTCCAGGTCCCCAAAGC; for GAPDH, the primers were GCACCGTCAAGGCTGAGAAC and ACTGGCGTC TTCACCACCAT. Each experiment was performed in triplicate and the average was calculated.
Methylation-specific PCR and sodium bisulfite genomic sequencing of RUNX3 promoter Genomic DNA was extracted by a standard proteinase K digestion and phenol/chloroform procedure. Genomic DNA was modified by bisulfite treatment as described previously (Herman et al., 1996) . After modification, PCR amplification was performed with 40 cycles at 95 1C for 30 s, 67-71 1C for 30 s and 72 1C for 40 s in a thermal cycler (Bioneer, Korea). The primer sequences for the unmethylated products were forward, 5 0 -TTATGAGGGGTGGTTGTATGTGGG-3 0 , reverse, 5 0 -AAAACAACCAACACAAACACCTCC-3 0 ; for the methylated products, forward, 5 0 -TTACGAGGGGCGGTCG TACGCGGG-3 0 , reverse, 5 0 -AAAACGACCGACGCGAA CGCCTCC-3 0 . Methylated and unmethylated PCR products were purified enzymatically using a presequencing kit (Amersham Life science, OH, USA) as recommended by the manufacturer, and then subjected to direct sequencing using a BigDye terminator (Applied Biosystems). Sequencing reactions were run on an ABI 3100 automated sequencer (Applied Biosystems) and data were analysed with DNA sequencing analysis 3.7 software (Applied Biosystems). Bisulfite sequencing was performed in both directions using the same primers used for PCR amplification.
Western blot analysis
Western blot analysis was performed as previously described (Johnson et al., 2003) . Antibodies specific to human proteins were anti-HDAC1 (Santa Cruz, CA, USA), antiacetyl-histone H3, antidimethyl-histone H3 (Lys9), antitrimethyl H3 (Upstate, NY, USA), anti-green fluorescent protein (GFP) (Santa Cruz), anti-G9a (Upstate), anti-Suv39h1 (Upstate) and anti-RUNX3 (Active motif, CA, USA).
Chromatin immunoprecipitation assay A ChIP assay was performed using a ChIP assay kit (Upstate) according to the manufacturer's protocol with slight modifications. Briefly, cells were cross-linked with 1% formaldehyde (Sigma, MO, USA) in a culture medium at RT for 10 min. Cells were then suspended in SDS lysis buffer (1% SDS, 10 mM EDTA, 50 mM Tris pH 8.1 and 1 Â protease inhibitor) and sonicated on ice. Next, the chromatin solution was precleared, incubated with antiacetyl-histone H3 or antidimethyl-histone H3 (Lys 9) antibodies (Upstate), and immune complexes were eluted. DNA recovered from the immunoprecipitated complex was subjected to PCR with 35 cycles. The primers for the RUNX3 gene promoter were forward, 5 0 -GGTTGCAGAAGTCACA GG-3 0 ; reverse, 5 0 -AATTTGCTTAGAACGTCCG-3 0 ). PCR products were separated on 2% agarose gels. DNA bands were visualized and semiquantified using the ImageJ program (NIH, Bethesda, MD, USA).
Immunofluorescent assay
After cells were fixed with 4% paraformaldehyde, immunofluorescence was performed as described previously (Johnson et al., 2003) . The slides were examined under fluorescence microscopy at Â 400 magnification (Carl Zeiss, AG, Germany).
Transient transfection and siRNA silencing
We transfected gastric cancer cells with full-length GFP-G9a, GFP-G9a-DSET mutant, full-length HDAC1 and HDAC1 mutant expression vectors using WelFect Transfection Reagent kit according to the manufacturer's protocol (WelGene, Daegu, Korea). Two double-stranded siRNAs designed to target G9a and HDAC1, respectively (Qiagen, Valencia, CA, USA) and a scrambled siRNA were synthesized (Samchully Pharm Co., Seoul, Korea). MKN1 cells were transfected with doublestranded RNAs using a HiPerFect Transfection reagent (Qiagen) according to the manufacturer's protocol. G9a and HDAC1 mRNA expression was evaluated by RT-PCR at 24 h post-transfection. siRNA no. 1 and no. 2 for G9a were designed to target 5 0 -AAGCTCTAACTGAACAACTAA-3 0 and 5 0 -CACC ATGAACATCGATCGCAA-3 0 , and siRNAs for HDAC1 were designed to target 5 0 -CACCCGGAGGAAAGTCTGTTA -3 0 and 5 0 -GACGAGTCCTATGAGGCCATT-3 0 .
Statistical analysis
The analysis of variance tests were performed to assess significant differences between control and experimental groups. The level of significance was set at Po0.01 or Po0.05. Results are presented as the mean ± s.d..
